In both rodent and cell culture models , CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus .
In rodent models , CBD was found to attenuate alcohol-induced hepatotoxicity , specifically , alcohol-induced steatosis .
Finally , findings from pre clinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking , alcohol self-administration , withdrawal-induced convulsions , and impulsive discounting of delayed rewards .
In human studies , CBD was well tolerated and did not interact with the subjective effects of alcohol .
Collectively , given its favorable effects on alcohol-related harms and addiction phenotypes in pre clinical models , CBD appears to have promise as a c and i date AUD pharmacotherapy .
This is further bolstered by the absence of abuse liability and its general tolerability .
There is substantial interest in the therapeutic potential of cannabidiol ( CBD ) , a nonpsychoactive cannabinoid found in plants of the genus Cannabis .
The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a c and i date pharmacotherapy for alcohol use disorder ( AUD ) .
Placebo-Controlled Trial of Zonisamide for the Treatment of Alcohol Dependence
Introduction : Zonisamide is an anticonvulsant medication with GABAergic , glutamatergic , and monoaminergic effects . Zonisamide has also been shown to reduce alcohol intake in rodents and in risky drinkers in the context of a laboratory study . This pilot clinical trial evaluated the safety , tolerability , and efficacy of zonisamide for the treatment of alcohol dependence . Methods : Forty alcohol-dependent subjects ( 23 men ) were r and omly assigned to receive treatment with either placebo or zonisamide in a 12-week double-blind trial . Zonisamide was initiated at a dosage of 100 mg/d , which was increased by 100 mg/d every 2 weeks for 8 weeks to a maximum dosage of 500 mg/d . The medication was continued for 4 weeks at the target dosage and then tapered and discontinued . The primary outcomes were drinks per week , heavy drinking days per week , and abstinent days per week , which were measured using the Timeline Follow-Back method . Results : There was a significant medication by treatment week interaction effect favoring the zonisamide group for heavy drinking days ( HDD ; P = 0.012 ) , drinks per week ( P = 0.004 ) , and alcohol urge scores ( P = 0.006 ) . There was not a significant effect on the number or rate of increase in abstinent days . There were no serious adverse events reported and zonisamide treatment was well tolerated . Conclusion : The findings provide preliminary support for the use of zonisamide to treat alcohol dependence . Efforts to replicate and extend these findings are warranted
In both rodent and cell culture models , CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus .
In rodent models , CBD was found to attenuate alcohol-induced hepatotoxicity , specifically , alcohol-induced steatosis .
Finally , findings from pre clinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking , alcohol self-administration , withdrawal-induced convulsions , and impulsive discounting of delayed rewards .
In human studies , CBD was well tolerated and did not interact with the subjective effects of alcohol .
Collectively , given its favorable effects on alcohol-related harms and addiction phenotypes in pre clinical models , CBD appears to have promise as a c and i date AUD pharmacotherapy .
This is further bolstered by the absence of abuse liability and its general tolerability .
There is substantial interest in the therapeutic potential of cannabidiol ( CBD ) , a nonpsychoactive cannabinoid found in plants of the genus Cannabis .
The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a c and i date pharmacotherapy for alcohol use disorder ( AUD ) .